Analysts expect Innoviva to report Q3 2026 revenue of approximately $115.31 million and an EPS of $0.49, while the current stock price of $21.22 remains significantly below the average analyst price target of $40.67.
Investors are zeroed in on the stability of the core GSK respiratory royalty portfolio, which generated $58.6 million in the first quarter of 2026. This cash flow is vital for funding the company’s strategic transition into an operating infectious disease business via Innoviva Specialty Therapeutics.
Recent clinical data for NUZOLVENCE has bolstered sentiment, but the market is seeking proof of commercial momentum for XACDURO to offset the long-term volatility of legacy royalty assets.